Qingdao University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Qingdao China (1909)

Organization Overview

First Clinical Trial
2006
NCT00968929
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

7.The Affiliated Hospital of Qingdao University | Affiliated hospital of Qingdao University | Affiliated Hospital of Qingdao University | Cao Yu | Hospital of Qingdao University | Liangzhou Wei | Qingdao University | Qingdao University Hospital | The Affiliated Hospital of Medical College of Qingdao University | The Affiliated Hospital of Qingdao University | The affilited hospital of medical college,Qingdao university | the study director of phase I clinical research center | wangdabo | Yantai City Hospital for Infectious Diseases | Yantai City Hospital for Infectious Diseases Immunotherapy center | Yantai Infectious Diseases Hospital | Yantai Yuhuangding Hospital

Active Ingredients

Drugs in Phase 4 Trials (36)

allogeneic cord blood (1 trial)

amoxicillin (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bismuth (1 trial)

Bismuth Subcitrate Potassium (Pylera) (1 trial)

butorphanol (stadol) (1 trial)

cisplatin (platinol) (5 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

cyclosporine (sandimmune) (2 trials)

dexamethasone (1 trial)

dexmedetomidine (precedex) (1 trial)

domperidone (1 trial)

entecavir (baraclude) (1 trial)

esketamine (spravato) (1 trial)

esomeprazole (nexium) (2 trials)

etoposide (vepesid) (4 trials)

fentanyl (Innovar) (2 trials)

fluticasone (cutivate) (1 trial)

gemcitabine (gemzar) (1 trial)

mesna (mesnex) (1 trial)

metronidazole (flagyl) (1 trial)

mosapride (1 trial)

naltrexone (revia) (1 trial)

pantoprazole (protonix) (1 trial)

pegaspargase (oncaspar) (1 trial)

propofol (diprivan) (1 trial)

ruxolitinib (jakafi) (1 trial)

salmeterol (serevent) (1 trial)

sargramostim (leukine) (2 trials)

streptokinase (streptase) (1 trial)

tetracycline (tetrex) (1 trial)

urea (4 trials)

urokinase (kinlytic) (1 trial)

vonoprazan (Voquezna) (1 trial)

xingnaojing (1 trial)

Drugs in Phase 3 Trials (34)

allopurinol (zyloprim) (1 trial)

ambrisentan (letairis) (1 trial)

azacitidine (vidaza) (2 trials)

borneol (1 trial)

bortezomib (velcade) (1 trial)

caffeic acid (1 trial)

capecitabine (xeloda) (3 trials)

cytarabine (cytosar-u) (1 trial)

danshen (1 trial)

decitabine (dacogen) (2 trials)

docetaxel (taxotere) (2 trials)

febuxostat (uloric) (1 trial)

ferric citrate (AURYXIA) (1 trial)

gefitinib (iressa) (1 trial)

glucose (1 trial)

Homoharringtonine (1 trial)

immune globulin (human) (Gamastan) (1 trial)

lapatinib (tykerb) (2 trials)

mercaptopurine (purinethol) (1 trial)

nadroparin (2 trials)

naproxen (naprosyn) (1 trial)

paclitaxel (taxol) (2 trials)

pertuzumab (perjeta) (2 trials)

platelets (1 trial)

rc48-adc (1 trial)

rituximab (rituxan) (2 trials)

rivaroxaban (xarelto) (3 trials)

sevelamer (renagel) (1 trial)

sildenafil (viagra) (1 trial)

sumatriptan (zecuity) (1 trial)

thrombopoietin (2 trials)

venetoclax (venclexta) (1 trial)

vinorelbine (navelbine) (3 trials)

warfarin (coumadin) (2 trials)

Drugs in Phase 2 Trials (25)

al8326 (2 trials)

alprostadil (prostin) (1 trial)

anlotinib (2 trials)

autologous cytokine induced killer cells (2 trials)

bifidobacterium bifidum (1 trial)

chickpea (1 trial)

chidamide (1 trial)

cytokine induced killer cells (2 trials)

dasatinib (sprycel) (1 trial)

dendritic cells (1 trial)

diphenhydramine (benadryl) (1 trial)

Epimedium (1 trial)

epirubicin (ellence) (1 trial)

erlotinib (tarceva) (1 trial)

f-627 (Ryzneuta) (1 trial)

irinotecan (Camptosar) (1 trial)

lactobacillus casei (1 trial)

lenalidomide (revlimid) (1 trial)

lorazepam (ativan) (1 trial)

monosialoganglioside (1 trial)

prednisone (meticorten) (1 trial)

selinexor (Xpovio) (1 trial)

tenecteplase (tnkase) (1 trial)

toripalimab (1 trial)

umbilical cord mesenchymal stem cells (6 trials)

Drugs in Phase 1 Trials (26)

abiraterone (zytiga) (1 trial)

amlodipine (norvasc) (1 trial)

anastrozole (arimidex) (2 trials)

autologous tumor infiltrating lymphocytes (2 trials)

beinaglutide (1 trial)

cefprozil (cefzil) (1 trial)

colchicine (colbenemid) (1 trial)

curcumin (2 trials)

dalpiciclib (1 trial)

dolutegravir (tivicay) (1 trial)

echinacoside (1 trial)

eldecalcitol (1 trial)

ezetimibe (zetia) (1 trial)

irbesartan (avapro) (1 trial)

itraconazole (sporanox) (1 trial)

levamlodipine (Conjupri) (1 trial)

liraglutide (victoza) (1 trial)

lisinopril (zestril) (1 trial)

metformin (glucophage) (1 trial)

mudan (1 trial)

nifedipine (procardia) (1 trial)

oseltamivir (tamiflu) (1 trial)

rifampin (1 trial)

shr7280 (1 trial)

sitagliptin (januvia) (1 trial)

xzp-3621 (2 trials)

Drugs in Other Trials (23)

125-iodine (1 trial)

amantadine (symmetrel) (1 trial)

autologous adipose-derived mesenchymal stem cells (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

autologous natural killer cells (1 trial)

cd19 car-t cells (1 trial)

epinephrine (levophed) (1 trial)

epoetin (Epogen) (1 trial)

furosemide (lasix) (1 trial)

jinhua qinggan (1 trial)

morphine (1 trial)

omacetaxine (synribo) (1 trial)

platelet-rich plasma (2 trials)

remimazolam (Byfavo) (1 trial)

ropivacaine (naropin) (1 trial)

roxadustat (1 trial)

sacubitril (Entresto) (1 trial)

sunitinib (sutent) (1 trial)

tafluprost (zioptan) (1 trial)

temozolomide (temodar) (1 trial)

tianqi pingchan (1 trial)

tranexamic acid (cyklokapron) (1 trial)

valsartan (diovan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Aplastic (Phase 4)

Arteriosclerosis (Phase 2)

Arteriosclerosis Obliterans (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cardiovascular Diseases (Phase 3)

Cerebral Infarction (Phase 4)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetic Foot (Phase 2)

Digestive System Neoplasms (Phase 2)

Embolism (Phase 4)

Esophageal Neoplasms (Phase 3)

Fibrosis (Phase 4)

Gastrointestinal Neoplasms (Phase 2)

Gastroparesis (Phase 4)

Glioma (Phase 2)

Gout (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hepatoblastoma (Phase 4)

Hyperphosphatemia (Phase 3)

Hypertension (Phase 3)

Hypertension, Portal (Phase 4)

Hypertension, Pulmonary (Phase 3)

Immunoblastic Lymphadenopathy (Phase 2)

Ischemia (Phase 4)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Liver Cirrhosis (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 4)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 4)

Lymphoma, T-Cell (Phase 4)

Malnutrition (Phase 1)

May-Thurner Syndrome (Phase 3)

Neoplasms (Phase 2)

Neuroblastoma (Phase 4)

Neurotoxicity Syndromes (Phase 2)

Neutropenia (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Embolism (Phase 4)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Retinoblastoma (Phase 4)

Small Cell Lung Carcinoma (Phase 3)

Stroke (Phase 4)

Thrombocytopenia (Phase 3)

Thromboembolism (Phase 4)

Thrombosis (Phase 3)

Ulcer (Phase 2)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 105
  • # of Trial APIs: 144